Mitomycin

The international reputation of the Faculty continues to be well served through its various exchange programs, including the Cultural Production project supported by Human Resources Development Canada see Partnerships, above ; . Several Fine Arts faculty members are serving in an executive capacity in international professional associations in their fields, among them the World Dance Association and the International Organization of Scenographers, Technicians and Architects of Theatre. Locally, the Faculty's commitment to ethnocultural diversity gave rise to a new summer outreach program developed collaboratively with Toronto's Harbourfront Centre, offering intensive, noncredit cultural workshops to the public in conjunction with Harbourfront's flagship community arts festival, World's Fare. In 2002- 03 the Faculty of Fine Arts made a concerted effort to improve its research environment and to increase the number of research applications submitted by faculty members to external granting agencies, especially SSHRC. Initial steps taken include the establishment of a Faculty Research Committee, the development of a framework to introduce Research Release Grants, and the development of a position for a Faculty-based Research Officer. Several Fine Arts faculty have joined the Culture and Entertainment Working Group in the Office of the Vice-President, Research and Innovation. Throughout the year, Fine Arts worked pro-actively with York's restructured Communications and Media Relations divisions to integrate and support the University's newly defined brand and visual identity program. The Faculty continued to invest considerable effort in internal and external public relations activities to increase awareness of the many accomplishments of Fine Arts faculty and students, with positive results. Special honours and accomplishments in 20022003 include: Film & Video professor Janine Marchessault was awarded a Canada Research Chair in Art, Digital Media and Globalization to study new media artists and their collaborations with institutions and cultural industries. Based on their winning proposal, third-year design students Graham Huber, Peter Hui and Gigi Lui were commissioned to design both the personal patch for Canadian Space Agency astronaut Steve MacLean and the patch to be worn by all the crew members of NASA's Space Shuttle mission STS-115 12A.
Effect of exposure of tumor cells to H2O2 or heat shock on B7-1 and B7-2 surface expression We have previously shown that in vitro exposure of MOPC-315 or P815 tumor cells to L-PAM, -irradiation, or mitomycin C leads to selective up-regulation of B7-1 surface expression, and that this up-regulation of B7-1 expression occurs at the transcriptional level 15 ; . Because reactive oxygen species were reported to be induced following exposure of cells to these anticancer modalities 26 29 ; , and to be important mediators of gene activation 20, 26, 28 ; , experiments were undertaken to determine whether exposure of MOPC-315 or P815 tumor cells to H2O2 can also lead to selective up-regulation of B7-1 surface expression. Accordingly, MOPC315 or P815 tumor cells were exposed in vitro for 15 min to H2O2 and then cultured for an additional 2224 h before B7-1 or B7-2 surface expression was assessed. Because similar results were obtained with MOPC-315 and P815 tumor cells, we elected to present the data obtained with P815 tumor cells because untreated P815 tumor cells, unlike untreated MOPC-315 tumor cells, are negative not only for B7-1surface expression but also for B7-2 surface expression 15, 18 ; . As seen in Fig. 1A, in vitro exposure of P815 tumor cells to H2O2 at a concentration ranging from 0.03 to 1.0 mM led to up-regulated B7-1 surface expression. The same preparation of P815 tumor cells remained negative for B7-2 surface expression even when exposed to 1.0 mM H2O2 Fig. 1B ; . Thus, H2O2 mimics the effect of L-PAM, -irradiation, and mitomycin C on B7-1 surface expression on tumor cells. Experiments were next conducted to determine whether exposure of P815 tumor cells to a different type of stress, heat shock, would also result in selective up-regulation of B7-1 surface expression. For this purpose P815 tumor cells were incubated for 2 h at 42C and then transferred to 37C for an additional 2224 h, before B7-1 and B7-2 surface expression was assessed. As a reference point, the same batch of P815 tumor cells was exposed in vitro to L-PAM or H2O2. As seen in Fig. 2, although exposure of P815 tumor cells to L-PAM or H2O2 led to up-regulated B7-1 surface expression, heat shock treatment did not lead to elevated B7-1 surface expression. Thus, not all types of stress lead to elevated B7-1 surface expression on P815 tumor cells.
Fig. 1. Time profiles for the uptake of [3H]17 -estradiol 17 -D-glucuronide E217 G ; into basolateral membrane vesicles BLMVs ; . Jejunum A ; , ileum B ; , and colon C ; BLMVs were incubated in medium containing 70 nM [3H]E217 G in the presence of 5 mM ATP E ; or 5 AMP F ; . Each point and vertical bar represents the mean SE of 3 determinations. The results in l mg protein ; are given by dividing the amount of [3H]E217 G associated with BLMVs pmol mg protein ; by the isotope concentration in the medium pmol l ; . AJP-Gastrointest Liver Physiol VOL. In a prospective, comparative evaluation of therapy in advanced gastrointestinal carcinoma with 5-fluorouracil, mitomycin C, and 1, 3-bis- 2-chlorethyl ; -l-nitrosourea used alone, in double combination, and in triple combination, 215 adults with proved gastrointestinal adenocarcinoma were randomly assigned to one of seven possible treatment programs. Dosages and schedules were determined from the results of a pilot program to allow comparable toxicity when administered over a comparable time between the programs. Objective evaluation of the overall results at 8 weeks indicates that the effectiveness of the drug combinations did not exceed that of the component drugs used alone. Combined 5-fluorouracil and 1, 3-bis- 2-chlorethyl ; -l-nitrosourea therapy might be preferentially effective for gastric and pancreatic carcinoma, but further study will be required for more definitive evaluation of this possibility. 3. Carmo-Pereira J, Costa FO, Henriques E et al. A comparison of two doses of adriamycin in the primary chemotherapy of disseminated breast carcinoma. Br J Cancer 1987; 56: 471-3. Frederiksen PL, Joergensen ST. Roesdahl K et al. Activity of adriamycin in metastatic breast cancer resistant to a combination regimen with cyclophosphamide, methotrexate, 5-fluorouracil, vincristine and prednisone. Cancer Treat Rep 1978; 621 449-50 Jain KK, Casper ES, Geller NL et al. A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer. J Clin Oncol 1985, 3. 818-26. Richards MA, Hopwood P, Ramirez AJ. Doxorubicin in advanced breast cancer: Influence of schedule on response, survival and quality of life. Eur J Cancer 1992; 28A 6-7 ; : 1023-8. 7. Sterner R, Stewart JF, Cantwell BMJ et al Adriamycin alone or combined with vincristine in the treatment of advanced breast cancer. Eur J Cancer Clin Oncol 1983, 19: 1553-7. Mouridsen HT. Systemic therapy of advanced breast cancer. Drugs 1992; 44: 17-28 Suppl 4 ; . 9. Harris JR, Morrow M, Bonadonna G. Cancer of the breast. In DeVita T Jr, Hellman S, Rosenberg SA eds ; : Cancer- Principles and Practice of Oncology, Fourth edition. Philadelphia: Lippincott 1993; 1264-332. 10. Von HofT DD, Layard MW, Basa P et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91: 710-7. Chevallier B, Fumoleau P, Kerbrat P et al. Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: A phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 1995; 13: 314-22. Fumoleau P, Chevallier B, Kerbrat P et al. A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: Report of the Clinical Screening Group of the EORTC. Ann Oncol 1996, 7: 165-71. Hudis CA, Seidman AD, Crown JPA et al. Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. J Clin Oncol 1996; 14- 58-65. Trudeau ME, Eisenhauer EA, Higgins BP et al. Docetaxel in patients with metastatic breast cancer: A phase II study of the National Cancer Institute of Canada - Clinical Trials Group. J Clin Oncol 1996; 14- 422-8 ten Bokkel Huinink WW, Prove AM, Piccart M et al phase II trial with docetaxel Taxotere * ; in second-line treatment with chemotherapy for advanced breast cancer Ann Oncol 1994; 5: 527-32. Ravdin PM, Burns HA, Cook G et al Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant metastatic breast cancer. J Clin Oncol 1995; 13: 2879-85. Valero V, Holmes FA, Walters RSet al. Phase 11 trial of docetaxel: A new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 1995, 13: 2886-94. Dieras V, Chevallier B, Kerbrat P et al. A multicentre phase II study of docetaxel 75 mg m 2 as first-line chemotherapy for patients with advanced breast cancer: Report of the Clinical Screening Group of the EORTC. Br J Cancer 1996; 74: 650-6. Adachi l, WatanabeT, Takashima S et al late phase II study of RP56976 docetaxel ; in patients with advanced or recurrent breast cancer. Br J Cancer 1996, 73: 210-6. Nabholtz JM, Senn HJ, Beswoda WR et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-contaimng chemotherapy J Clin Oncol 1999; 17: 1413-24. Bonneterre J, Roche H, Monnier A et al. Phase III study: Docetaxel versus 5-fluorouracil + navelbine in patients with metastatic breast cancer as 2nd line chemotherapy. Breast Cancer Res Treat 1998; 50- 223 Abstr ; 22. Sjostrom J, Blomqvist C, Mouridsen H et al. Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: A randomised phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer 1999: 35: 1194-201. Chan S, Friedrichs K. Noel D et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 1999: 17: 2341-54. Fumoleau P, Seidman AD. Trudeau ME et al. Docetaxel: A new active agent in the therapy of metastatic breast cancer. Exp Opin Invest Drugs 1997; 6: 1853-65. Van Oosterom AT. Schnjvers D. Docetaxel Taxotere ; : A review of preclinical and clinical experience. Part 2: Clinical experience. Anticancer Drugs 1995; 6: 356-63. Anon: Taxotere Docetaxel - International Product Monograph, Second edition. Rhone-Poulenc Rorer 1996; 68. Behar A, Lagrue G, Cohen-Boulakla Fet al. Capillary filtration in idiopathic cyclic edema. Effects of Daflon 500. Nuklearmedizin 1988; 27: 105-7. Rowinsky EK. Donehower RC. Antimicrotubules agents In Chabner BA. Longo DL eds ; . Cancerchemotherapy and Biotherapy: Principles and Practice, second edition. Philadelphia: Lippincott-Raven; 263-75. Canobbio L. Boccardo F. Pastorino G et al. Phase II study of Navelbine in advanced breast cancer. Semin Oncol 1989; 16: 33-6 Suppl 4 ; . Bruno S, Lira-Puerto V. Texeira L et al. Phase II trial with vinorelbine Navelbine ; in the treatment of advanced breast cancer Ann Oncol 1992; 3 Suppl 1 ; : 126. Garcia-Conde J. Lluch A, Casado A el al. Phase II trial with Navelbine in advanced breast cancer previously untreated. Breast Cancer Res Treat 1992, 23. 142 Abstr 52 ; . Fumoleau P, Delgado FM. Delozier T et al. Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 1993: II: 1245-52. Weber B, Vogel C, Jones S et al. A US multicenter phase II trial of Navelbine in advanced breast cancer. Proc Soc Clin Oncol 1993; 12: 61 Abstr ; . Romero A, Rabinovich MG. Vallejo CTet al. Vinorelbine as firstline chemotherapy for metastatic breast cancer J Chn Oncol 1994. 12. 336-41. Fumoleau P, Delozier T. Extra JM et al. Vinorelbine navelbine ; in the treatment of breast cancer: The European experience. Semin Oncol 1995: 22 Suppl 5 ; : 22-9. Weber BL, Vogel C, Jones S et al. Intravenous vinorelbine as firstline and second-line therapy in advanced breast cancer. J Clin Oncol 1995; 13. 2722-30. Gasparini G, Caffo O. Barni S el al. Vinorelbine 1 an active antiproliferative agent in pre-treated advanced breast cancer patients: A phase II study. J Clin Oncol 1994, 12: 2094-101. Jones S. Winer E. Vogel C et al. Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer. J Clin Oncol 1995; 13: 2567-74. Hortobagyi GN. Future directions for vinorelbine Navelbine ; . Semin Oncol 1995: 22: 80-7. Smith GA Current status of vinorelbine for breast cancer. Oncology 1995; 9. 767-73. Bissery MC, Vrignaud P. Lavelle F. Preclinical profile of docetaxel Taxotere ; : Efficacy as a single agent and in combination. Semin Oncol 1995; 22 Suppl 13 ; : 3-16. Bissery MC, Vrignaud P. Lavelle F. In vivo evaluation of docetaxel Taxotere ; and vinorelbine Navelbine ; as single agents and in combination in mammary tumour models. In: Calvo F, Crepin M, Magdelenat H eds ; : Breast Cancer. Advances in Biology and Therapeutics. Montrouge. France: John Libbey Eurotext 1996; 265-72. Miller AB, Hoogstraten B. Staquet M et al. Reporting results of cancer treatment. Cancer 1981: 47: 207-14. Vergniol JC, Bruno R, Montay G et al. Determination of taxotere in human plasma by a semi-automated high performance liquid chromatographic method. J Chromatogr 1992; 582: 273-8. Puozzo C, Ung H. Zorza G. New sensitive method for simultaneous detection of vinorelbine and 17-deacetyl-vinorelbine in human biological fluids. J Chromatogr Sci in press.

Of attachment to the cell Table 5 ; . Phages B3, D3, E79, F116, G101, PB1, and P04 contain DNA, PP7 and 7S contain RNA, whereas the composition of C5 and M6 remains to be determined 6, 7, 8, ; . Some of these phages utilize polar pili for adsorption, whereas others either are not known to be pilus dependent or have been shown to attach nonselectively to the bacterial wall and hence have been listed as cell wall phages Table 5 ; 7, 42, D. E. Bradley and T. L. Pitt, J. Gen. Virol., in press ; . Each phage was propagated on PU21 and then titered on PU21, PU21 pMG1 ; , or PU21 pMG2 ; to determine the efficiency of plating. Plasmidcontaining strains had only a slight reduction in the efficiency of plating pilus phages C5, F116, P04, PP7, and 7S, but did not propagate pilus phage M6 or cell wall phages B3, D3, E79, G101, or PB1 Table 5 ; . Actually, with undiluted lysates of phage B3 minute plaques were observed, and with undiluted phage D3 there was partial lysis, but propagation did not occur in either case and host-modified phage could not be detected. Interference with propagation occurred at a stage subsequent to phage adsorption since adsorption of B3, D3, E79, G101, PB1, and M6 by PU21 and PU21 pMG2 ; was equivalent Table 6 ; . Effect of pMGl and pMG2 on pyocin type. Another commonly used technique for characterizing P. aeruginosa isolates is pyocin typing. PU21, like most P. aeruginosa 26 ; , is pyocinogenic, and by the cross-streaking plate technique of Gillies and Govan 22 ; it inhibited seven of eight primary indicator strains and four of five in an additional subset Table 7 ; . Remarkably, PU21 pMG1 ; and PU21 pMG2 ; had no pyocin activity against these indicators and thus became pyocin nontypable. Farmer and Herman have developed another procedure for pyocin typing that utilizes mitomycin C in broth culture to induce pyocin formation. Lysates are then spot tested against 27 indicator strains 19 ; . By this technique, PU21 had pyocin activity for 20 of 27 indicators Table 8 ; . Again the R plasmids interfered with.

Portion of cells arrested in S phase in WRN and WRN LCLs. We found similar increases in % S phase cells after CDDP and mitomycin C treatment of WRN and WRN LCLs and modicon. The activities of the AWRI, research, development and knowledge transfer, will be conducted for the benefit of all Albertans and implemented within the values enunciated for all Alberta Ingenuity initiatives: Excellence The AWRI will pursue only excellent research and innovation and support only the best people identified through a rigorous peer review process. This process will ensure the highest standards of quality are met as determined by stringent peer reviews and by an internationally-recognized scientific advisory board. Alberta Ingenuity's International Science and Engineering Advisory Committee members will be involved, as appropriate, to ensure a robust international standard of excellence. Pan-Alberta The AWRI will bring together stakeholders from public and private organizations across the province that have the capacity for research and innovation. These stakeholders may include Alberta industry leaders, companies, Alberta's three major research Universities, Alberta colleges and technical institutes, government research organizations, other research institutes, and associations. Collaborative The AWRI will enable and nurture mutually supportive collaborations between and among science and engineering researchers and innovators, water managers and decision makers, industry research and innovation leaders with a focus on the pan-Alberta scope of the initiative. Success will be built on establishing and sustaining provincial, national, and international research collaborations and developing effective industry partnerships. Another study, it was also shown that mitomycin C is mainly activated by cytochrome P450 reductase to DNA binding adducts in COS1 cells expressing human cytochrome P450 reductase. Only at high concentrations of mitomycin C did DT-diaphorase play a role in the activation Joseph et al., 1996 ; . Another clinically used prodrug, tirapazamine, is a bioreductive agent that is activated by a one-electron reduction by cytochrome P450 reductase to a cytotoxic nitroxide radical intermediate before further reduction to the nontoxic metabolite SR 4317 3-amino-1, 2, ; Walton et al., 1989; Brown, 1993; Denny and Wilson, 2000 ; Table 5 ; . Because the nitroxide radical is quenched by molecular oxygen under aerobic conditions, it has been shown to cause selective toxicity by both DNA alkylation and formation of hydroxyl radicals in hypoxic cells Brown, 1993 ; . Although and molindone.
The chemotherapy and its hydrophilic properties. Extensive peritonectomy causes a small increase in drug clearance. The area under the curve ratio of intraperitoneal to intravenous drug is dependent on the rate of diffusion across the peritoneal-plasma barrier and the rate of drug metabolism or excretion from the plasma. 1.11.2 The possibility of intraperitoneal chemotherapy administration as an alternative to its systemic delivery in patients with resectable gastric cancer was raised over a decade ago. 93 ; In six randomized studies, in patients with gastric cancer it was associated with a decreased incidence of peritoneal spread and a tendency for improved survival. 94 ; In another phase III randomized trial, patients with stage III gastric cancer, T3-4 tumors serosal invasion ; and N1 lymph nodes regional resectable ; had a marked survival advantage compared to those treated with surgery alone. 95 ; 1.11.3 As with every method of regional chemotherapy, the pharmacokinetic advantage of intraperitoneal chemotherapy is limited to the abdominal and pelvic surfaces. 96 ; Also, intraperitoneal chemotherapy acts mainly by direct diffusion of drug and high concentration tissue penetration is limited to 1-2 mm from the surface. 97-99 ; That is why perioperative intraperitoneal distribution of a drug carrying solution before adhesions are formed is crucial for its therapeutic effect. 91-93 ; Studies in patients with pseudomyxoma peritonei treated by cytoreductive surgery and intraperitoneal chemotherapy demonstrated that cancer tends to recur on unexposed surfaces not treated due to a compromised distribution of intraperitoneally administered drug. 100 ; 1.12 Pharmacokinetics and pharmacodynamics of intraoperative intraperitoneal chemotherapy Duration of exposure of cancer cells to the regional chemotherapy are important for the effectiveness of intraperitoneal chemotherapy. At the same time, intraoperative administration prolongs operative time. It is obvious that duration of intraperitoneal chemotherapy should be limited to the shortest reasonable period of time. In vitro studies of human gastrointestinal cancer cells exposed to chemotherapeutic drugs for 1 hour have demonstrated that concentrations of 10 mcg ml of mitomycin C and cisplatin produced cytotoxic effect in 70-80% of cancer cells. 101 ; Pharmacokinetic studies of intraoperative intraperitoneal chemotherapy demonstrated that 75% to 90% mitomycin C and cisplatin was absorbed during the first hour. 102, 103 ; Consequently, duration of intraoperative intraperitoneal chemotherapy should be approximately one hour. 1.13 Hyperthermic potentiation of chemotherapy effect There are several ways of potentiating cytotoxic effects of chemotherapy and among them is hyperthermia. It can help overcome drug resistance by increasing tissue penetration, inhibiting cell repair mechanisms and by temperature.
14: 103-112 1971 ; , disclose several derivatives of mitomycin substituted in the 1a, 7, and 9a positions and moxifloxacin. Modeling Nonlinear Neural Dynamics with Volterra-Poisson Kernels special session Se ; Spiros Courellis, Ghassan Gholmieh, Vasilis Marmarelis and Theodore W. Berger.
Mitomycin bioreductive enzymes known to be present in these cells, i.e. NADPH cytochrome c P450 ; reductase, DT diaphorase, and NADHcytochrome b5 reductase. To ascertain the degree of resistance of MCRA-expressing cell lines to MC and POR, a clonogenic assay was performed under both aerobic and hypoxic conditions Fig. 3 ; . Profound resistance to the mitomycins was observed under aerobic conditions in the MCRA-expressing cell lines, compared with parental cells, at drug concentrations as high as 500 M Fig. 3 A and C ; . Cell survival was not affected by drug exposure times of up to hours after treatment with 80 M MC data not shown ; . In contrast, parental CHO cells were extremely sensitive to the mitomycins at these high drug concentrations under aerobic conditions, with surviving fractions that were several orders of magnitude less than those observed in MCRA-expressing cells Fig. 3 A and C ; . Most human and animal tumor-cell lines display an even greater sensitivity to these agents than the relatively resistant CHO cells 2123 ; . Under hypoxic conditions, the MCRA-expressing cells were almost as sensitive to the mitomycins as the parental cell and mrv.
Caverject Dual Chamber 10micrograms injection Caverject Dual Chamber 20micrograms injection Clinomel N4-550 intravenous infusion 2 litre Clinomel N4-550 intravenous infusion 2.5 litre Clinomel N6-900 intravenous infusion 2.5 litre Clinomel N7-1000 intravenous infusion 1 litre Clinomel N7-1000 intravenous infusion 1.5 litre Compleven intravenous infusion 2.5 litre Decubal cream 50g Econac 75mg 3mL injection Fersamal tablets Glutafin GF pasta shells 500g Harifen LP white chip cookies 200g Menopur 75iu injection pdr for recon ; + solvent Mitomycin C Kyowa 40mg injection pdr for recon. 1. The provider uses proper infection-prevention procedures. 2. The woman receives an injection of local anesthetic under the skin of her arm to prevent pain during implant removal. This injection may sting. She stays fully awake throughout the procedure and multivitamin.

Role of GSH on radiation- and Blem-treated cells 36. Edsmyr, F., Andersson, L. and Esposti, P.L. 1985 ; Combined bleomycin and radiation therapy in carcinoma of the penis. Cancer, 56, 12571263. 37. Tabata, T., Takeshima, N., Nishida, H., Hirari, Y. and Hasumi, K. 2003 ; A randomized study of primary bleomycin, vincristine, mitomycin and cisplatin chemotherapy followed by radiotherapy versus radiotherapy alone in stage IIIB and IVA squamous cell carcinoma of the cervix. Anticancer Res., 23, 28852890. 38. Nagata, J., Kijima, H., Hatanaka, H., Asai, S., Miyachi, H., Takagi, A., Miwa, T., Mine, T., Yamazaki, H., Nakamura, M., Kado, T., Scanlon, K.J. and Ueyama, Y. 2001 ; Reversal of cisplatin and multidrug resistance by ribozyme-mediated glutathione suppression. Biochem. Biophys. Res. Commun., 286, 406413. Received on February 16, 2005; revised on April 29, 2005; accepted on June 11, 2005.
Close window pharmacy clinical policy bulletins aetna medicare prescription drug plan subject: antineoplastics, injectable status - alkeran® inj melphalan ; x x epirubicin etoposide x fludarabine leucovorin calcium x x methotrexate x x mitomycin mitoxantrone octreotide sandostatin lar® octreotide ; thiotepa toposar™ etoposide ; x zoladex® goserelin acetate 6mg ; x avastin® bevacizumab ; busulfex® busulfan ; x x dacogen® decitabine ; x eloxatin® oxaliplatin ; etopophos® etoposide phosphate ; x faslodex® fulvestrant ; fludara® fludarabine ; mutamycin® mitomycin ; novantrone® mitoxantrone ; plenaxis® abarelix ; x proleukin® aldeskeukin ; x rituxan® rituximab ; x torisel® temsirolimus ; zoladex® goserelin acetate 1 8mg ; x depo-provera® medroxyprogesterone ; x x sandostatin® octreotide ; x - & reg; & trade; sm & nbsp; & reg; & trade; sm ; & reg; & trade; sm x x x policy: precertification criteria medicare part b vs medicare part d review criteria under medicare prescription drug benefit plans, including plans that use an open or closed formulary, alkeran inj , busulfex , etopophos , etoposide , leucovorin , methotrexate and toposar are subject to review because they may be considered to be either a medicare part b drug or a medicare part d drug and murine.

This study was supported by grants from the National Institutes of Health: Fogarty International Center 5 F05 TW05442-02 J.A.C. HL49999 L.P.T. ; and HL49041, HD24492, HL51735 C.P.W. Strain surveillance is important for the detection and monitoring of escape variants, for the monitoring of population immunity, and serves as an early warning system. There is no sentinel system in place for the systemic collection of B. [para]pertussis strains. Clinical isolates are sent to the RIVM for confirmation or classification on an ad hoc basis. At the RIVM, strains are serotyped en genotyped. Serotyping characterizes the fimbrial [sero]types produced by the bacteria. This is relevant since fimbriae are important protective antigens and are used in a number of acellular pertussis vaccines.4244 Furthermore, there is evidence that Fim2 strains are more virulent than Fim3 strains.45 Finally, changes in frequencies of fimbrial serotypes are associated with changes in population immunity and may serve as an early warning system.46 Genotyping is used to detect shifts in the B. [para]pertussis population, which may reflect changes in population immunity. In addition, genotyping is used to characterize the genes for proteins, which are part of pertussis vaccines. This allows the detection and monitoring of escape variants.47 Strain surveillance has revealed major shifts in the Netherlands B. pertussis population.47-50 In general vaccine-type surface proteins have been replaced by novel types. Strains used for the production of acellular vaccines originate from the 1940s to 1950s and consequently there is a mismatch between acellular vaccines and circulating strains. Several studies have indicated that strain variation affects vaccine efficacy in the mouse model.51-53 The mismatches between vaccine strains and circulating strains are relatively minor, and may be less relevant in recently immunized individuals. However, strain variation may be important in individuals with waning immunity. In fact, there is a very direct temporal relationship between the most recent shift in the B. pertussis population and the current pertussis epidemic.50 In summary, strain surveillance has provided evidence that the emergence of escape variants has played an important role in the pertussis epidemics in the Netherlands.54, 55.

Bladder cancer is an important cause of morbidity and mortality, and, in contrast to the United States, its incidence and mortality rates are still increasing in European countries, even though the majority of new cases are diagnosed as early and superficial tumors 1, 2 ; . Transitional cell carcinomas of the bladder can be classified into two groups with distinct behavior and different molecular profiles: a ; low-grade tumors, which include papillary and usually superficial lesions; and b ; high-grade tumors, which comprise papillary and nonpapillary, often invasive lesions. Superficial cancers Ta-T1 stages ; account for 70 80% of newly diagnosed bladder cancers. First-line treatment is transurethral resection, fulguration, or laser coagulation, but approximately two-thirds of patients develop recurrences, with a progression of grade and stage despite the macroscopically complete eradication of the primary lesion 35 ; . The high rate of recurrence and stage progression represents an important challenge for the correct management of these patients. Intravesical therapy is usually given, but, up to now, no treatment has resulted in a significant improvement in overall survival. Intravesical immunotherapy with Bacillus Calmette-Guerin BCG ; is currently the most effective approach for the therapy and prophylaxis of superficial bladder cancer 3, 57 ; , but it is associated with serious morbidity 5, 8, 9 ; . Moreover, only two-thirds of patients respond to BCG treatment, and, among these, one-third are destined to relapse 1, 4 ; . An improvement in overall survival has also never been demonstrated 5 ; . Up now, antiblastic agents such as thiotepa, doxorubicin, epidoxorubicin EPI ; , and mitomycin C used intravesically in clinical trials on large case series have not proven capable of significantly reducing disease progression or improving overall survival 6, 10, 11 ; . Valrubicin, which was used recently as a second-line intravesical chemotherapy in BCG-refractory patients, produced complete responses in only 20% of cases 12, 13 ; . Therefore, cystectomy represents the treatment of choice for these patients. A great deal of interest has been focused on research into new drugs or new drug combinations for intravesical chemotherapy. Gemcitabine GEM ; has proven to be effective when systemically administered to advanced bladder cancer patients 14 16 ; and is also active, with minimal bladder irritation, in instillation treatment 4, 17 ; . EPI has been shown to be active as a single agent in intravesical therapy 18 20 ; . the present study, we investigated the cytotoxic activity of GEM and EPI and their interaction in two human bladder cancer cell lines by reproducing local infusion or systemic. MATERIALS AND METHODS Bacterial strains, plasmids, colicin A, and bacteriophage. The bacterial strains used in this study are listed in Table 1. To construct the cpxA + plasmid pOK101, a 1.5-kilobase cpxA + , BamHI-EcoRI restriction fragment was cloned into the pINIII Ipp5 lacPO ; A3 laclIq expression vector 17 ; digested with BamHI and EcoRI. The cpxA + fragment consisted of the 1, 508-base-pair DraI-StuI fragment previously described 37 ; , along with surrounding polylinker DNA from the pUC19 cloning vector. The cloned fragment consists almost entirely 1, 374 base pairs; 37 ; of the cpxA coding sequence. Expression of cpxA in pOK101 is nominally from the lpp and lac promoters of the vector. Immunooverlay Western ; blot analysis showed higher CpxA levels when transformants were induced, but CpxA protein accumulation over background could be detected even in the absence of an inducer R. Harris, unpublished observation ; . Colicin A was prepared from Citrobacter freundii CA31 induced with mitomycin C 0.1 , ug ml ; , essentially as previously described 36 ; . After induction, cells were killed by the addition of 0.1 volume of chloroform. Debris was removed by sedimentation at 10, 000 x g for 10 min. The supernatant fluid was used without further purification. Bacteriophages R17 and P1 vir were from our laboratory stocks. Bacterial media and growth. Luria broth LB ; medium and Vogel-Bonner minimal medium were as previously described 19 ; . For determining amikacin resistance, we used either minimal medium or a medium consisting of LB in Vogel-Bonner salts base; the resistance phenotype of some mutants was weak on LB medium itself. Solid media were prepared with 15 g of agar per liter. Minimal media were supplemented routinely with 0.2% glucose or fructose for p.fkA deletion strains ; and 40 jig of required amino acids and thymidine per ml. Unless indicated otherwise, ampicillin and amikacin Sigma Chemical Co., St. Louis, Mo. ; were added at 100 , ug ml and 12 , ug ml, respectively. Bacteria were and mitotane. Figure 5. Coronary resistance at the level of epicardial stenosis top ; and in distal microcirculation middle ; at the various steps of the protocol as indicated in Figure 1. Bottom panel shows the behavior of total coronary resistance and the contribution of stenosis black ; and microvascular resistance white columns ; . Coronary resistance was not calculated during balloon coronary occlusion. During ischemia, both coronary stenosis and distal microcirculation showed a significant increase in resistance to flow * p 0.05 vs. baseline, p 0.05 vs. adenosine; p 0.05 vs. max ischemia.

The hESC lines KhES-1, -2, and -3 were established in our laboratory [7]. Cells were maintained on a feeder layer of embryonic day-12.5 mouse embryonic fibroblasts MEFs ; mitotically arrested with mitomycin C Mutamycin; BristolMyers Squibb Company; Princeton, NJ, : bms. com ; in Dulbecco's modified Eagle's medium Ham's F-12 medium Sigma-Aldrich, St. Louis, : sigmaaldrich. com ; supplemented with 20% knockout serum replacement KSR ; Invitrogen, Carlsbad, CA, : invitrogen. com ; , 2 mM L-glutamine, 1% minimal essential medium nonessential amino acids, 0.1 mM -mercaptoethanol, and 5 ng ml recombinant human basic fibroblast growth factor bFGF ; FGF-2 ; Upstate Biotechnologies, MA, : upstatebiotech ; . Every 35 days, the ESCs were partially dissociated by CTK solution containing 1 mg ml collagenase, 0.25% trypsin, 20% KSR, and 1 mM CaCl2 in phosphate-buffered saline PBS ; supplemental Fig. 2A ; [7]. They were then collected as a larger cell mass by centrifugation for 3 minutes at 1, 000 rpm and seeded onto a MEF feeder layer. The use of hESC lines were performed in conformity with The Guidelines for Derivation and Utilization of Human Embryonic Stem Cells 2001 ; of MEXT the Ministry of Education, Culture, Sports, Science and Technology ; , Japan. Chayama, and Hiromitsu Kumada The significance of hepatitis B virus DNA detected in hepatocellular carcinoma of patients with hepatitis C Yoshizumi Shintani, Hiroshi Yotsuyanagi, Kyoji Moriya, Hajime Fujie, Takeya Tsutsumi, Tadatoshi Takayama, Masatoshi Makuuchi, Satoshi Kimura, and Kazuhiko Koike PANCREAS C25.9 ; Closing the gastrin loop in pancreatic carcinoma: Co-expression of gastrin and its receptor in solid human pancreatic adenocarcinoma Jens Peter Goetze, Finn C. Nielsen, Flemming Burcharth, and Jens F. Rehfeld Ductal lesions in patients with chronic pancreatitis show K-ras mutations in a frequency similar to that in the normal pancreas and lack nuclear immunoreactivity for p53 Jutta Lttges, Anke Diederichs, Martin A. O. H. Menke, Ilka Vogel, Bernd Kremer, and Gnter Klppel A Phase II trial of biweekly high dose gemcitabine for patients with metastatic pancreatic adenocarcinoma Herbert Ulrich-Pur, Gabriela V. Kornek, Markus Raderer, Karin Haider, Werner Kwasny, Dieter Depisch, Renate Greul, Bruno Schneeweiss, Gwendolyn Krauss, Josef Funovics, and Werner Scheithauer GASTROINTESTINAL TRACT C26.9 ; Intraperitoneal chemohyperthermia with mitomycin C for digestive tract cancer patients with peritoneal carcinomatosis Annie C. Beaujard, Olivier Glehen, Jean L. Caillot, Yves Francois, Jacques Bienvenu, Gilles Panteix, Florence Garbit, Eric Grandclment, Jacques Vignal, and Franois N. Gilly Intestinal metaplasia is the probable common precursor of adenocarcinoma in Barrett esophagus and adenocarcinoma of the gastric cardia Alberto Ruol, Anna Parenti, Giovanni Zaninotto, Stefano Merigliano, Mario Costantini, Matteo Cagol, Rita Alfieri, Luigi Bonavina, Alberto Peracchia, and Ermanno Ancona BLOOD BONE MARROW C42.1 ; The clinical significance of CD34 expression in response to therapy of patients with acute myeloid leukemia: An overview of 2483 patients from 22 studies Yoshinobu Kanda, Tamae Hamaki, Rie Yamamoto, Aki Chizuka, Miyuki Suguro, Tomohiro Matsuyama, Naoki Takezako, Akiyoshi Miwa, Masahiro Kami, Hisamaru Hirai, and Atsushi Togawa SKIN C44.9 ; Ultrasound examination of regional lymph nodes significantly improves early detection of locoregional metastases during the follow-up of patients with cutaneous melanoma: Results of a prospective study of 1288 patients Andreas Blum, Bettina Schlagenhauff, Waltraud Stroebel, Helmut Breuninger, Gernot Rassner, and Claus Garbe BREATS C50.9 ; Accuracy of sentinel lymph node biopsy in patients with large primary breast tumors. Figure 2. Diagram shows pyramidal hierarchy of evidence used by clinicians, researchers, and administrative decisionmakers to evaluate medical technology for possible use in the KP Southern California Region. Reproduced by permission of the publisher from: SUNY Downstate Medical Center, Medical Research Library of Brooklyn. SUNY Downstate Medical Center evidence based medicine tutorial [home page on the Internet]. [Brooklyn NY ; : SUNY Downstate Medical Center]; 2005 [updated 2004 Jan 6; cited 2005 Nov 14]. Available from: : library.downstate EBM2 contents .1. Persistence of Mycobacterium tuberculosis infection despite prolonged chemotherapy is a major problem in tuberculosis control 3 ; . Hypoxic dormant bacilli are, in contrast to oxic replicating organisms, not effectively killed by conventional antimycobacterials and could be one of the factors contributing to the persistence 1 ; . Metronidazole 7 ; , nitrofurantoin 4 ; , and PA-824 a nitroimidazopyran ; 5 ; are the first leads that show activity against dormant bacteria. The compounds appear to act as prodrugs that require reduction of their nitro group to reactive intermediates that then cause damage and death of the bacilli. The finding that prodrugs that require reduction to unfold their antimicrobial activity are effective against hypoxic dormant bacilli prompted us to question whether mitomycin C might possess antidormancy activity. This drug is used in the chemotherapy of hypoxic solid tumours and requires reduction to become biologically active 6 ; . Here, we report the analysis of the antimicrobial activity of mitomycin C on growing and dormant Mycobacterium bovis BCG Pasteur ATCC 35734. Mitomycin C showed an MIC 4 ; of 5 1.7 ng ml ; . agreement with our previous report, a 104-fold-higher MIC 50 M ; of nitrofurantoin was observed and metronidazole did not show inhibition of growth MIC of metronidazole 1, 000 M ; 4 ; . Figure 1A shows that mitomycin C at MIC appears to be bacteriostatic. Incubation of growing cultures with 10 times the MIC of mitomycin C 50 nM ; resulted in a 104-fold decrease in viability after 5 days. To grow dormant organisms, we employed the Wayne dormancy culture system. Wayne's model is based on growth of the bacilli in sealed tubes with stirring. Initially the cultures grow exponentially and consume oxygen. A temporal oxygen gradient is generated, and when oxygen is depleted the cultures enter stationary phase. The hypoxic stationary-phase bacteria do not replicate but maintain viability; they are in a state of dormancy 2, 8 ; . Figure 1B shows that exposure of dormant bacilli to 500 nM mitomycin C resulted in a 30-fold reduction in viable counts after 5 days. To achieve a kill that was similar to that observed for mitomycin C, a 1, 000fold higher concentration of nitrofurantoin was required: 500 M nitrofurantoin reduced viability of the dormant culture 90-fold after exposure for 5 days, while 500 M metronidazole reduced viability of the oxygen-starved culture only 2-fold after exposure for 5 days 4 ; . Comparison of the activities of mitomycin C against growing Fig. 1A ; and dormant Fig. 1B ; cultures shows that the growing bacilli were more sensitive to the drug. Furthermore, it is interesting to note the difference in the exposure time-kill curves for growing and dormant cultures. Growing cultures were killed as expected ; in an exposure time-dependent fashion. In contrast hypoxic cultures appear to lose viability rapidly 10-fold, and then the CFU level off. Whether this indicates the presence of a mitomycin Cresistant subpopulation in the dormant culture remains to be elucidated. In conclusion, the comparison of the effects of mitomycin C and the nitroheterocyclic drugs on dormant bacilli revealed that mitomycin C showed activity at a 1, 000-fold-lower concentration. Furthermore, mitomycin C showed a drastically lower MIC.
And Cesium -137 are the main sources of gamma rays used in mutation breeding. They are stored in lead containers when not in use and operated by remote control mechanisms to irradiate plant material. 3.1.2 UV RAYS Ultraviolet light has limited penetrating ability, therefore its use is limited to treating spores, pollen grains cells and cultured tissue. Wavelengths in the range of 2, 500 to 2, 800 nm are biologically most effective because this is the region of maximal light absorption by nucleic acids. 3.1.3 BETA PARTICLES Beta particles such as those from Phosphorus-32 and Sulfur- 35 produce effects in tissues similar to those of X- or gamma rays. The penetrating ability of beta particles is lower than that of X- and gamma rays. The lower penetrating ability of beta particles can be overcome by putting the radioisotope in a solution and administering them to the plant material. P-32 and S-35 may then be incorporated directly into cell nucleus giving a somewhat greater localization of the site of action. But, because of the variability from tissue to tissue and cell to cell, it is difficult to determine the exact dose given by an internal emitter in plant material. 3.1.4 NEUTRONS Neutrons have been shown to be highly effective for the induction of mutation in plants but, a certain degree of confusion exists concerning the results of early experiments and due to lack of adequate dosimetric techniques. 3.1.5 ION BEAMS Ion beams can give a large amount of energy with high LET Linear Energy Transfer ; to the localized position in tissues. Therefore, we can expect different biological effects will be given to plant materials compared with low LET radiations, such as, gamma- and x-rays. Also ion beams can produce large structural changes in chromosomes and DNA. So we can expect to induce different kinds of mutations in plants with high frequency than gamma- and x- rays. But further basic and practical researches should be made to use ion beams efficiently in the future. 3-2 CHEMICAL MUTAGENS The number of chemical mutagens is numerous and continuously increasing. But for mutation inductin in cultivated plants only a few are readily very useful and most of them belong to the special calss of alkylating agents such as, ethyl methane sulhonate EMS ; , diethyl sulfate dES ; , ethyleimine EI ; , ethyl nitroso urethane ENU ; , ethyl nitroso urea ENH ; , and methyl nitroso urea MNH ; . A number of workers also found azides as effective mutagens. 3.2.1 BASE ANALOGUES AND RELATED COMPOUNDS True base analogues are closely related to DNA bases, adenine, guanine, cytosine or thymidine and can be incorporated into DNA without affecting its replication. But analogue differs from the normal base in certain substitutes hence its electronic structure is modified and it can be expected that occasional pairing errors will occur at the time of DNA replication after the analogue has been incorporated. The most frequently used analogues are 5-bromo-uracil BU ; and 5-bromo-deoxyuridine BUDR ; , which are analogues of thymine. Apart from true analogues, it has been found that N-methylated oxypurines have a chromosome effect. The most efficient compounds are 8-ethoxy caffeine EOC ; and 1, 3, 7, tetramethyluric acid TMU ; , but their mode of action is still unknown. Maleic hydrazide MH ; , an isomer of uracil, induces chromosome breaks in cell and aberrations are localized in heterochromatic regions near the centromere of the chromosomes. 3.2.2 ANTIBIOTICS Antibiotics such as azaserine, mitomycin C, streptonigrin and actinomycin D have been found to have chromosome breaking properties, but their usefulness are limited. 3.2.3 ALKYLATING AGENTS This is the most important group of mutagenic chemicals for mutation induction in cultivated plants. They have one or more reactive alkyl groups which can be transferred to other molecules. They react 13.
DPN receive equal exposure. Pincus et al.17 found that patients on both MTX and low-dose prednisolone had better long-term drug continuation than those on MTX alone; there was no effect on the discontinuation rates of the other DMARDs studied. Utley et al. have recently questioned the validity of Kaplan-Meier plots when applied to drug studies in rheumatology.21 They argue that the underlying assumptions upon which Kaplan-Meier analysis depend may not hold, particularly when recruitment into a study takes place over an extended time period. For example, we cannot assume that a hypothetical ; patient recruited in 1989 and started on MTX experiences the same ADR hazard as a patient recruited in 1999. Similarly, two patients recruited in 1989 and started on MTX, one immediately and one 5 years later after unsuccessful treatment with two other DMARDs, may not experience the same hazard of discontinuation from ADRs or inefficacy. Intuitively, it seems unlikely that these assumptions will hold. At the very least, improvements in our practice over the last 13 years ensure that patients we see in our clinics today start DMARDs earlier in their disease, receive folic acid with their MTX22 and are provided with appropriate information, reassurance and ready access to a telephone helpline. The distinction between a statistically different survival curve and a meaningful clinical difference is a key point. Whether the underlying reasons are purely pharmacological or not, courses of MTX given in our clinical cohort were clearly continued for longer than other DMARDs. The slight differences seen between SAS, myocrisin and DPN are less likely to be of clinical relevance despite their `statistical significance'. We have tried to present incidence and time-course data unadorned, and point out only the clear clinical differences in our experience of monitoring these drugs.